danmaku icon

Moderna 177% after initial melanoma results showed its personalized vaccine with Merc

0 View7 hours ago

Moderna surged 177% after initial melanoma results showed its personalized vaccine with Merck's Keytruda outperformed Keytruda alone in recurrence-free and metastasis-free survival. The companies did not disclose the duration of that benefit or whether patients lived longer overall.
warn iconRepost is prohibited without the creator's permission.
creator avatar

Recommended for You

  • All
  • Anime